Category: Cancer

Regorafenib, sold under the brand name Stivarga among others, is an oral multi-kinase inhibitor developed by Bayer which targets angiogenic, stromal and oncogenic receptor tyrosine kinase (RTK). Regorafenib shows anti-angiogenic activity due to its dual targeted VEGFR2-TIE2 tyrosine kinase inhibition. Since 2009 it was studied as a potential treatment option in multiple tumor types.[1] By 2015 it had two US approvals for advanced cancers. Contents 1 Approvals and indications... [wikipedia]

1 Discussion

Related Brands

Drugs with the same active ingredients

Popular Topics


quelle expérience avez vous de ce traitement ?...